AU2003291314B2 - Methods for treating migraine - Google Patents

Methods for treating migraine Download PDF

Info

Publication number
AU2003291314B2
AU2003291314B2 AU2003291314A AU2003291314A AU2003291314B2 AU 2003291314 B2 AU2003291314 B2 AU 2003291314B2 AU 2003291314 A AU2003291314 A AU 2003291314A AU 2003291314 A AU2003291314 A AU 2003291314A AU 2003291314 B2 AU2003291314 B2 AU 2003291314B2
Authority
AU
Australia
Prior art keywords
migraine
subject
antagonist
glucocorticoid
cortisol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003291314A
Other languages
English (en)
Other versions
AU2003291314C1 (en
AU2003291314A1 (en
Inventor
Joseph K. Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2003291314C1 publication Critical patent/AU2003291314C1/en
Publication of AU2003291314A1 publication Critical patent/AU2003291314A1/en
Application granted granted Critical
Publication of AU2003291314B2 publication Critical patent/AU2003291314B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2003291314A 2002-11-05 2003-11-05 Methods for treating migraine Ceased AU2003291314B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42419902P 2002-11-05 2002-11-05
US60/424,199 2002-11-05
PCT/US2003/035328 WO2004041214A2 (en) 2002-11-05 2003-11-05 Methods for treating migraine

Publications (3)

Publication Number Publication Date
AU2003291314C1 AU2003291314C1 (en) 2004-06-07
AU2003291314A1 AU2003291314A1 (en) 2004-06-07
AU2003291314B2 true AU2003291314B2 (en) 2007-07-26

Family

ID=32312768

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003291314A Ceased AU2003291314B2 (en) 2002-11-05 2003-11-05 Methods for treating migraine
AU2003291322A Ceased AU2003291322B2 (en) 2002-11-05 2003-11-05 Methods for treating gastroesophageal reflux disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003291322A Ceased AU2003291322B2 (en) 2002-11-05 2003-11-05 Methods for treating gastroesophageal reflux disease

Country Status (6)

Country Link
US (2) US7361646B2 (enExample)
EP (2) EP1581234A4 (enExample)
JP (3) JP2006508951A (enExample)
AU (2) AU2003291314B2 (enExample)
CA (2) CA2504751C (enExample)
WO (2) WO2004041214A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
CA2649894A1 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
ES2626131T3 (es) * 2007-10-17 2017-07-24 Laboratoire Hra Pharma Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
KR101245604B1 (ko) 2007-11-13 2013-03-21 메리테이지 파마, 인크. 코르티코스테로이드 조성물
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US20150209374A1 (en) 2014-01-29 2015-07-30 Faro Owiesy Composition and Method for Curing Migraine Headaches
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5697112A (en) * 1996-11-08 1997-12-16 Glaxo Wellcome Inc. Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
HUP0201243A3 (en) 1999-04-30 2002-11-28 Pfizer Prod Inc Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
AU2002361861A1 (en) * 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kettel et al. Fertility and Sterility. Vol. 56, no.3 1991 *

Also Published As

Publication number Publication date
WO2004041214A3 (en) 2004-11-11
EP1567167A4 (en) 2007-09-12
WO2004041215A3 (en) 2004-11-04
CA2504697A1 (en) 2004-05-21
AU2003291314C1 (en) 2004-06-07
WO2004041215A2 (en) 2004-05-21
JP2006507311A (ja) 2006-03-02
CA2504751A1 (en) 2004-05-21
JP2006508951A (ja) 2006-03-16
AU2003291322A1 (en) 2004-06-07
US7361646B2 (en) 2008-04-22
EP1581234A4 (en) 2007-09-12
JP2011021044A (ja) 2011-02-03
CA2504697C (en) 2012-03-13
US20040132703A1 (en) 2004-07-08
EP1581234A2 (en) 2005-10-05
AU2003291322B2 (en) 2008-09-25
CA2504751C (en) 2013-02-05
EP1567167A2 (en) 2005-08-31
AU2003291314A1 (en) 2004-06-07
US20040167110A1 (en) 2004-08-26
WO2004041214A2 (en) 2004-05-21
US8450379B2 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
AU2003291314B2 (en) Methods for treating migraine
US6680310B2 (en) Methods for preventing antipsychotic-induced weight gain
US20210128584A1 (en) Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis
AU2002319665A1 (en) Methods for preventing antipsychotic-induced weight gain
US8097606B2 (en) Antiglucocorticoids for the treatment of catatonia
US20060052354A1 (en) Methods for treating migraine
HK1061526B (en) Methods for preventing antipsychotic-induced weight gain

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 AUG 2007.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 AUG 2007

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired